Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash from Financing Activities: 2022-2025

Historic Cash from Financing Activities for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to $9.3 million.

  • bioAffinity Technologies' Cash from Financing Activities rose 458.15% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 million, marking a year-over-year increase of 338.44%. This contributed to the annual value of $5.6 million for FY2024, which is 1731.26% up from last year.
  • Latest data reveals that bioAffinity Technologies reported Cash from Financing Activities of $9.3 million as of Q3 2025, which was up 209.50% from $3.0 million recorded in Q2 2025.
  • bioAffinity Technologies' Cash from Financing Activities' 5-year high stood at $15.0 million during Q3 2022, with a 5-year trough of -$563,556 in Q4 2022.
  • For the 3-year period, bioAffinity Technologies' Cash from Financing Activities averaged around $1.7 million, with its median value being $1.0 million (2025).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 127.65% in 2023, then spiked by 3,412.08% in 2025.
  • Quarterly analysis of 4 years shows bioAffinity Technologies' Cash from Financing Activities stood at -$563,556 in 2022, then surged by 84.95% to -$84,805 in 2023, then skyrocketed by 2,488.86% to $2.0 million in 2024, then soared by 458.15% to $9.3 million in 2025.
  • Its Cash from Financing Activities was $9.3 million in Q3 2025, compared to $3.0 million in Q2 2025 and $1.0 million in Q1 2025.